The morally ground-shifting legacy of Ian Wilmut and Dolly the sheep
By Gregory E. Kaebnick,
STAT
| 09. 15. 2023
Ian Wilmut, the British scientist behind the first-ever cloning of a mammal, died Sept. 10, leaving behind a twofold legacy. One part is groundbreaking science. Creating Dolly required a combination of genome manipulation and reproductive tools that helped launch what is sometimes called “reprogenetics,” a basket of reproductive and genetic technologies that allow for greater control over human procreation and generated work that ranges from human-animal chimeras to the “de-extinction” of mammoths. By demonstrating that differentiated adult cells could be forced by the right chemical signals to become pluripotent stem cells, Wilmut’s work also provided the basis for Shinya Yamanaka’s Nobel Prize-winning work.
Besides being groundbreaking science, Dolly was morally ground-shifting. Perhaps more than any other biotech advance, Dolly symbolized growing human power over nature. But the Dolly project was deeply troubling to most observers. Kept a close secret by the Roslin Institute and initially disclosed in a media leak in 1997, about eight months after her birth, Dolly caught everyone by surprise. At the same time, genetically modified crops were being rolled out quickly and...
Related Articles
By Emily Mullin, Wired | 11.14.2023
In a small initial test in people, researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol, the fatty substance that clogs and hardens arteries over time.
The gene-editing treatment aims to permanently lower cholesterol...
By Carissa Wong, Nature | 11.16.2023
In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The decision marks another high point for a biotechnology that has been lauded as revolutionary in the decade since...
By Emily Mullin, Wired | 11.16.2023
The first medical treatment that uses Crispr gene editing was authorized Thursday by the United Kingdom.
The one-time therapy, which will be sold under the brand name Casgevy, is for patients with sickle cell disease and a related blood disorder...
By Alexis Heng, UCA News | 11.13.2023
In recent years, Singapore has increasingly leveraged new reproductive technologies to overcome the country's rapidly aging demographics and dismal fertility rate, which hit a new low in 2022.
Hence, it would be timely for Singapore’s Bioethics Advisory Committee (BAC) to...